

References

I-152

1. Sarepta Therapeutics. An open-Label, multi-center study to evaluate the safety and tolerability of eteplirsen in early stage Duchenne muscular dystrophy. NLM Identifier: NCT02420379.
2. Mendell J, Goemans N, Lowes L, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Ann Neurol*. 2019;79:257-271.
3. Agboola F, Lin G, Fluetsch N, et al. The effectiveness and value of deflazacort and exon-skipping therapies for the management of Duchenne muscular dystrophy: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. *J Manag Care Spec Pharm*. 2020. 26(4):361-366.
4. Kinane TB, Mayer OH, Duda PW, et al. Long-term pulmonary function in Duchenne muscular dystrophy: Comparison of eteplirsen-treated patients to natural history. *J Neuromuscul Dis*. 2018;5(1):47-58.
5. McDonald C, Shieh P, Abdel-Hamid H, et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. *J Neuromuscul* 2021;8(6):989-1001.
6. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Eteplirsen.
7. Micromedex DrugDex Compendium®. Eteplirsen (Exondys 51).
8. Eteplirsen In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated date April 26, 2021.
9. Exondys 51 (eteplirsen), injection, for intravenous use [package insert]. Sarepta Therapeutics, Inc. Cambridge, MA. Revised 01/2022.